Equities

Oramed Pharmaceuticals Inc

Oramed Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)2.40
  • Today's Change0.07 / 3.00%
  • Shares traded105.28k
  • 1 Year change+3.00%
  • Beta1.7672
Data delayed at least 15 minutes, as of Oct 09 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Oramed Pharmaceuticals Inc. is a pharmaceutical company engaged in the research and development of pharmaceutical solutions with a technology platform. The Company has developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its Protein Oral Delivery (POD) technology is designed to protect drug integrity and increase absorption. Its pipeline includes ORMD-0801 (Oral Insulin) Diabetes, ORMD-0801 (Oral Insulin) NASH, and ORMD 0901 (Oral GLP-1). Its oral insulin (ORMD-0801) has the potential to create a new paradigm in the treatment of diabetes through oral delivery of insulin at an earlier stage of treatment. Its oral insulin capsule (ORMD-0801) has shown a reduction of liver fat content in early clinical trials. It is also developing an oral Glucagon-like peptide-1 (GLP-1) analog capsule (ORMD-0901), which is an incretin hormone that stimulates the secretion of insulin from the pancreas.

  • Revenue in USD (TTM)0.00
  • Net income in USD20.86m
  • Incorporated2011
  • Employees15.00
  • Location
    Oramed Pharmaceuticals Inc1185 AVENUE OF THE AMERICAS, 3RD FLOORNEW YORK 10036United StatesUSA
  • Phone+1 (646) 844-1164
  • Fax+1 (845) 818-3588
  • Websitehttps://oramed.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Allovir Inc0.00-140.34m93.49m112.00--0.7769-----1.23-1.230.001.040.00----0.00-67.85-52.85-73.72-57.72-------378,613.90----0.00-------12.87------
MDxHealth SA80.74m-40.80m95.05m300.00------1.18-1.54-1.543.06-0.32290.59069.397.49269,136.70-29.85-51.62-43.63-64.7262.6450.88-50.54-117.640.8252-1.741.18--89.4319.842.14--30.13--
Medicinova Inc1.00m-8.16m95.64m13.00--1.67--95.64-0.1665-0.16650.02041.170.0155----76,923.08-12.65-15.36-13.19-15.90-----816.49-1,182.54----0.00------39.08--15.87--
bluebird bio Inc54.90m-311.44m95.89m375.00--1.81--1.75-2.19-2.190.35740.27330.09093.21--146,400.00-51.54-34.75-80.31-40.84-37.34-124.35-567.29-5,770.410.5712-19.810.7827--720.04-11.588.00---30.47--
Bioatla Inc0.00-104.56m96.67m65.00--3.08-----2.18-2.180.000.64910.00----0.00-84.23-48.72-106.06-57.35-------6,651.71----0.00-------15.95---37.01--
Regulus Therapeutics Inc0.00-35.39m96.89m31.00--0.9869-----1.26-1.260.001.500.00----0.00-47.90-53.74-52.71-76.96-------715.58----0.00-------6.05--94.54--
Oramed Pharmaceuticals, Inc.0.0020.86m97.85m15.004.800.55074.67--0.49990.49990.004.360.00----0.0012.19--12.29--------------0.00---50.43--115.11------
Clearside Biomedical Inc7.52m-33.46m97.92m30.00------13.01-0.497-0.4970.1119-0.37850.2058--59.01250,800.00-91.51-63.57-107.97-81.7795.06---444.66-231.80--------519.89207.341.40--82.41--
Tiziana Life Sciences Ltd - ADR0.00-17.69m97.92m9.00--17.69-----0.1726-0.17260.000.05370.00----0.00-91.52-58.16-138.98-75.36------------0.0427-------14.90------
Anixa Biosciences Inc0.00-12.36m98.47m4.00--4.52-----0.3906-0.39060.000.67720.00----0.00-50.54-59.69-52.50-62.61-------6,040.10----0.00-----28.3627.83------
Beyondspring Inc1.88m-15.57m99.54m35.00------53.06-0.3987-0.39870.0481-0.7490.0698----52,111.11-59.75-75.50-102.15-96.48-----856.29-4,977.12--------29.61--36.82---13.54--
Agenus Inc159.63m-223.67m100.31m389.00------0.6284-11.27-11.278.03-11.420.4723--154.98410,357.30-68.45-55.02-281.52-115.3199.51---144.94-102.92---0.9185----59.4733.56-11.66--22.58--
Assembly Biosciences Inc21.48m-45.61m101.53m65.00--2.93--4.73-9.32-9.324.285.470.2362--125.62330,476.90-50.15-39.69-69.22-44.03-----212.33-409.24----0.00-----13.5134.23---5.59--
Data as of Oct 09 2024. Currency figures normalised to Oramed Pharmaceuticals Inc's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.